Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis

Revance Therapeutics, a biotechnology company developing botulinum toxin products for use in aesthetic and therapeutic indications, today announced initiation of...

Response Biomedical Corp. Announces Closing of First Tranche of Private Placement

VANCOUVER, BRITISH COLUMBIA–(Marketwired – June 17, 2016) – Response Biomedical Corp. (“Response” or the “Company”) (TSX:RBM)(OTC:RPBIF) announces the closing of...

ALPHAEON Announces Results from Two Phase III Trials of DWP-450 Botulinum Toxin Type A

ALPHAEON Corporation today announced positive data from two Phase III clinical trials of its DWP-450 botulinum toxin type A neuromodulator...

Revance Therapeutics Reports Interim Efficacy and Safety Results from Phase 2 Clinical Trial

Revance Therapeutics, Inc. (NASDAQ:RVNC) has reported interim efficacy and safety results from a Phase 2 clinical trial of the RT001...